PRKAG2 and cardiac hypertrophy: This multifaceted role of AMPK is further emphasized by clinical studies: gain-of-function mutations in PRKAG2, which encodes the AMPKγ2 regulatory subunit, are associated with congenital cardiac syndromes characterized by ventricular hypertrophy, conduction defects, and glycogen metabolism disorders [44–46].